DOCSLIB.ORG

140.Pdf (5.917Mb)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
140.Pdf (5.917Mb) A thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy Ibegbu, A. 2009. The effects of Hypoxia on neuronal cell signalling. PhD thesis. Queen Margaret University. Accessed from: http://etheses.qmu.ac.uk/140/ Repository Use Policy The full-text may be used and/or reproduced, and given to third parties for personal research or study, educational or not-for-profit purposes providing that: • The full-text is not changed in any way • A full bibliographic reference is made • A hyperlink is given to the original metadata page in eResearch eResearch policies on access and re-use can be viewed on our Policies page: http://eresearch.qmu.ac.uk/policies.html http://etheses.qmu.ac.uk THE EFFECTS OF HYPOXIA ON NEURONAL CELL SIGNALLING AUGUSTINE IBEGBU A thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy QUEEN MARGARET UNIVERSITY 2009 Table of Contents Contents Page No Title page i Table of contents ii-ix List of figures x-xiii List of plates xiv-xv List of tables xvi-xvii List of abbreviations and definition of terms xviii-xxii List of appendices xxiii-xxiv Declaration xxv Acknowledgements xxvi Abstract xxvii-xxix 1. CHAPTER ONE: Introduction 1 1.1. General Introduction 1-4 1.2. Signalling Overview 4-7 1.2.1. Neuronal cell signalling 8-10 1.2.2. Mechanism of signalling 10-12 1.2.3. Influence of membrane lipid on signalling 12-14 1.3. Receptors 15-17 1.3.1 G proteins 17-20 1.3.2. Heterotrimeric G proteins 21-24 1.3.3. The Gα subunit 24-26 1.3.4. The Gβγ dimer 26-27 1.3.5. The function of G protein βγ subunits 27-28 1.3.6. Modulation of heterotrimeric G proteins 28-29 1.3.7. G protein and ion channels 29-30 1.3.8 G proteins and MAPK 30-31 1.4. G proteins in disease 31-32 1.5. Second Messengers 32 1.5.1. Types of second messengers 32-33 1.5.2. Mechanisms of action of secondary messengers 33-34 ii 1.6. The nervous system 34-38 1.7. Hypoxia 38-43 1.7.1. Neuronal damage in hypoxia 43-49 1.7.2 Morphological and functional changes in hypoxia 49-51 1.7.3. Hypoxic disorders 52-53 1.8. Neuroprotection in hypoxia 53-55 1.9. Opioid receptor Agonists 56-58 1.9.1. Uses of opioids 58-59 1.9.2. Opioid receptor activation 59-62 1.10. Cannabinoids 63-65 1.10.1. Therapeutic potential of cannabinoids 66-71 1.10.2. Neuroprotection by cannabinoids 71-74 1.10.3. The role of cannabinoids in neuroinflammation 74-79 1.11. The interaction of opioids and cannabinoids 79-82 1.12. B50 Cells 82-83 1.13. Aim of the study 84 1.14. Objectives and hypotheses of the study 84 2. CHAPTER TWO: Method 85 2.1. Raising stable cells in culture 85 2.1.1. Introduction 102 2.1.2. Materials 102 2.1.3. Method 85-86 2.1.4. Method for freezing B50 cells 86 2.2. Total cell count and Viability 87 2.2.1. Introduction 87 2.2.2. Materials 87 2.2.3. Method 87-89 2.3. The effect of hypoxia on B50 neuronal cells in culture using LDH assay 89 2.3.1. Introduction 89-90 2.3.2. Materials 90 2.3.3. Method 90-91 iii 2.4. The effect of culture duration on LDH release from B50 cells in normal and hypoxic cultures 92 2.4.1. Introduction 92 2.4.2. Materials 92 2.4.3. Methods 92 2.5. Neuronal cell proliferation 92 2.5.1. Introduction 92-93 2.5.2. Materials 93 2.5.3. Method 94-95 2.6. Morphological studies 96 2.6.1. Introduction 96 2.6.2. Materials 96 2.6.3. Method 96-97 2.7. Neuronal B50 cell differentiation 97 2.7.1. Introduction 97 2.7.2. Materials 97 2.7.3. Method 98 2.8. Neuronal pattern and pattern formation 98 2.8.1. Introduction 98-99 2.8.2. Materials 99 2.8.3. Method 99 2.9. Cannabinoid (CB1) and Mu opioid receptor expression in neuronal B50 cells using semi-quantitative RT-PCR Method 99 2.9.1. Introduction 99-100 2.9.2. Extraction of total RNA 101 Introduction 101 Materials 101 Method 101-102 2.9.3. Semi-Quantitative One step RT-PCR Analysis 102 Introduction 102 Materials 103 Method 103 Programming of the thermal cycler 103 Preparation of Mater Mix 103- 104 Analysis of the RT-PCR products 104 iv 2.10. The effect of cannabinoid receptor agonists on B50 neuronal cell morphology, proliferation and viability 105 2.10.1 The effect on morphology 105 Introduction 105 2.10.2. Materials 105 2.10.3. Method 105-106 2.10.2 The effect of cannabinoid receptor agonists ± antagonists treatment on cellular proliferation in B50 cells in culture. 107 Introduction 107 Materials 107 Method 107-108 2.10.3. The effect of cannabinoid agonist ±antagonist on cellular viability using LDH release from neuronal B50 cells in culture. 109 Introduction 109 Materials 109 Method 109-113 2.11. The effect of opioid agonists on neuronal B50 cell morphology, proliferation and viability 114 2.11.1. The effect on morphology 114 Introduction 114 Materials 114 Method 114-115 2.11.2 The effect of opioid receptor agonists ± antagonists treatment on cellular proliferation in B50 cells in culture. 115 Introduction 115 Materials 115 Method 115-116 v 2.11.3 The effect of opioid agonist ± antagonist treatment on cellular viability using LDH release from B50 neuronal cells 116 Introduction 116 Materials 116 Method 117-119 2.12. The effect of DbcAMP on LDH release from B50 cells treated with cannabinoid and opioid agonists ± antagonists. 120 2.12.1. Introduction 120 2.12.2. Materials 120 2.12.3. Method 120-121 2.13. The effect of hypoxia on cAMP levels in cultured B50 cells: cAMP enzyme immunoassay (ELISA) method. 122 2.13.1. Introduction 122 2.13.2. Materials 122 2.13.3. Method 122-126 2.14 The effect of hypoxia on extracellular signal-regulated protein kinases (ERK) in cultured B50 neuronal cells: ERK1/2 enzyme immunoassay (ELISA) method 127 2.14.1. Introduction 127 2.14.2. Materials 127 2.14.3. Method 127-129 2.14.4 Method for phospho-ERK 1&2 assay in B50 cells 129 Well Arrangement 129 Assay incubation 129-130 Calculation of ERK concentration 130 2.15. Statistical Analysis 131 vi 3. CHAPTER THREE: Results 132 3.1. Cell Characteristics 133 3.1.1. B50 Cell culture 133 3.1.2. Morphological Studies 133 3.1.3. Pattern formation 134 3.1.4. Cell Count and Viability 139-143 3.1.5. B50 Cell Proliferation 144-146 3.1.6. Neuronal differentiation 146-147 3.1.7. LDH release from cultured B50 cells 148-149 3.2. Expression of cannabinoid CB1 and mu opioid (MOR) receptors in B50 neuronal cells using semi-quantitative RT-PCR 149 3.2.1 The effect of hypoxia on the expression of CB1 and MOR receptor mRNA in B50 cells 149-150 3.2.2. Semi quantitative RT-PCR of cannabinoid CB1 and MOR 150-156 3.3. Cannabinoid receptor agonist administration 157 3.3.1. The effect of cannabinoid treatment and pre-treatment on the morphology of cultured B50 cells 157-164 3.3.2. The effect of cannabinoid agonist treatment on cellular proliferation in normal and hypoxic cultured B50 cells 165-174 3.4. LDH release from neuronal B50 cells in culture using LDH assay. 175 3.4.1. LDH release from treatment with cannabinoid agonist/antagonist in B50 neuronal cells cultured in hypoxia. 175-181 3.4.2. LDH release from pre-treatment with cannabinoid agonist/antagonist in cultured B50 cells in hypoxia. 182-188 3.5. The effect of DbcAMP on LDH release from cultured B50 cells. 189 3.5.1 Effect of DbcAMP and cannabinoid agonist treatment ± antagonist on LDH release in cultured normal B50 cells. 189-192 vii 3.5.2 Effect of DbcAMP and cannabinoid agonists treatment and pre- treatment ± antagonist on LDH release in cultured B50 cells in hypoxia. 193-196 3.6 The concentration-dependent effect of a CB1 antagonist on cannabinoid agonist. 197 3.6.1 Concentration-dependent activity of a selective CB1 antagonist (AM251) on 10nM Win agonist treatment on LDH release in cultured B50 cells in hypoxia. 197-199 3.6.2 Concentration-dependent activity of a selective CB1 antagonist (AM251) on 10nM Win pre-treatment using LDH release in cultured B50 cells in hypoxia 200-202 3.7 Opioid receptor agonist administration 203 3.7.1. The effect of opioid treatment on the morphology of cultured B50 cells. 203-212 3.7.2. The effect of opioid agonist on cellular proliferation in normal and hypoxic cultured B50 cells. 213-220 3.8 Opioid receptor agonist effect on LDH 221 3.8.1 LDH release from treatment with opioid agonist ± antagonist in B50 neuronal cells cultured in hypoxia 221-224 3.8.2 LDH Release from opioid agonist and antagonist treated and pre- treated B50 cells cultured in hypoxia. 225-228 3.8.3. LDH Release from normal cultured B50 cells treated and pre- treated with opioid agonists. 229-231 3.9. Effect of hypoxia on signalling molecules 232 viii 3.9.1. The effect of hypoxia on cAMP levels in B50 cells treated with cannabinoid agonists 232-234 3.9.2.
Load more

Recommended publications
  • Lipid Metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives
    cancers Review Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives 1, 1, 1 2 1 Laurence Pellerin y, Lorry Carrié y , Carine Dufau , Laurence Nieto , Bruno Ségui , 1,3 1, , 1, , Thierry Levade , Joëlle Riond * z and Nathalie Andrieu-Abadie * z 1 Centre de Recherches en Cancérologie de Toulouse, Equipe Labellisée Fondation ARC, Université Fédérale de Toulouse Midi-Pyrénées, Université Toulouse III Paul-Sabatier, Inserm 1037, 2 avenue Hubert Curien, tgrCS 53717, 31037 Toulouse CEDEX 1, France; [email protected] (L.P.); [email protected] (L.C.); [email protected] (C.D.); [email protected] (B.S.); [email protected] (T.L.) 2 Institut de Pharmacologie et de Biologie Structurale, CNRS, Université Toulouse III Paul-Sabatier, UMR 5089, 205 Route de Narbonne, 31400 Toulouse, France; [email protected] 3 Laboratoire de Biochimie Métabolique, CHU Toulouse, 31059 Toulouse, France * Correspondence: [email protected] (J.R.); [email protected] (N.A.-A.); Tel.: +33-582-7416-20 (J.R.) These authors contributed equally to this work. y These authors jointly supervised this work. z Received: 15 September 2020; Accepted: 23 October 2020; Published: 27 October 2020 Simple Summary: Melanoma is a devastating skin cancer characterized by an impressive metabolic plasticity. Melanoma cells are able to adapt to the tumor microenvironment by using a variety of fuels that contribute to tumor growth and progression. In this review, the authors summarize the contribution of the lipid metabolic network in melanoma plasticity and aggressiveness, with a particular attention to specific lipid classes such as glycerophospholipids, sphingolipids, sterols and eicosanoids.
    [Show full text]
  • Cannabinoid Receptor Cannabinoid Receptor
    Cannabinoid Receptor Cannabinoid Receptor Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol. www.MedChemExpress.com 1 Cannabinoid Receptor Antagonists, Agonists, Inhibitors, Modulators & Activators (S)-MRI-1867 (±)-Ibipinabant Cat. No.: HY-141411A ((±)-SLV319; (±)-BMS-646256) Cat. No.: HY-14791A (S)-MRI-1867 is a peripherally restricted, orally (±)-Ibipinabant ((±)-SLV319) is the racemate of bioavailable dual cannabinoid CB1 receptor and SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent inducible NOS (iNOS) antagonist. (S)-MRI-1867 and selective cannabinoid-1 (CB-1) receptor ameliorates obesity-induced chronic kidney disease antagonist with an IC50 of 22 nM. (CKD). Purity: >98% Purity: 99.93% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg 2-Arachidonoylglycerol 2-Palmitoylglycerol Cat. No.: HY-W011051 (2-Palm-Gl) Cat. No.: HY-W013788 2-Arachidonoylglycerol is a second endogenous 2-Palmitoylglycerol (2-Palm-Gl), an congener of cannabinoid ligand in the central nervous system. 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119.
    [Show full text]
  • Cannabinoid Receptor-Mediated Modulation of Inhibitory Inputs to Mitral
    1 2 Cannabinoid Receptor-Mediated Modulation of Inhibitory Inputs to Mitral 3 Cells in the Main Olfactory Bulb 4 5 Ze-Jun Wang1*, Sherry Shu-Jung Hu2*, Heather B. Bradshaw3, Liqin Sun1, Ken Mackie3, 6 Alex Straiker3, and Thomas Heinbockel1 7 8 1Department of Anatomy, Howard University College of Medicine, Washington, DC 20059, USA; 9 2Department of Psychology, National Cheng Kung University, Tainan 701, Taiwan; 3The Gill 10 Center for Biomolecular Science and the Department of Psychological and Brain Sciences, 11 Indiana University, Bloomington, IN 47405, USA 12 13 Author contributions: Z.W., S.H., A.S., and T.H. designed research; Z.W., S.H., H.B., L.S., K.M., 14 A.S., and T.H. performed research; Z.W., S.H., K.M., A.S., and T.H. analyzed data; Z.W., S.H., 15 A.S. and T.H. wrote the paper. 16 17 *Z.W. and S.H. contributed to this work to a comparable extent. 18 19 Running head: Cannabinoid Receptor-Mediated Modulation of Mitral Cells 20 21 Contact Information: 22 Thomas Heinbockel, Dept. of Anatomy, Howard University College of Medicine, 520 ‘W’ Street, 23 NW, Washington, DC 20059; tel.: (202) 806-9873; fax: (202) 265-7055; email: 24 [email protected] 25 Downloaded from www.physiology.org/journal/jn at American Univ of Beirut (193.188.128.021) on June 20, 2019. 2 26 Non-standard abbreviations: Δ9-THC, Δ9-tetrahydrocannabinol; 2-AG, 2-arachidonoyl glycerol; 27 ABHD4/6/12, α/β-hydrolase domain 4/6/12; anandamide or AEA, N-arachidonoyl ethanolamine; 28 CB1 and CB2, cannabinoid receptor 1 and 2; DGLα/β, diacylglycerol lipase α and β;
    [Show full text]
  • University of Dundee MASTER of SCIENCE Novel Modulators Of
    University of Dundee MASTER OF SCIENCE Novel Modulators of Human Sperm Motility King, Louise Award date: 2014 Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 26. Sep. 2021 MASTER OF SCIENCE Novel Modulators of Human Sperm Motility Louise King 2014 University of Dundee Conditions for Use and Duplication Copyright of this work belongs to the author unless otherwise identified in the body of the thesis. It is permitted to use and duplicate this work only for personal and non-commercial research, study or criticism/review. You must obtain prior written consent from the author for any other use. Any quotation from this thesis must be acknowledged using the normal academic conventions. It is not permitted to supply the whole or part of this thesis to any other person or to post the same on any website or other online location without the prior written consent of the author.
    [Show full text]
  • Dehydroabietylamine Based on the Current Information A
    Health Canada Santé Canada STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S) Substance: Dehydroabietylamine Based on the current information available to the Office of Controlled Substances, it appears that the above substance is: Controlled ☐ Not Controlled X under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s): There are no reports that the substance is an efficacious cannabinoid receptor agonist and therefore it cannot be included under item 1 of Schedule II to the CDSA. Prepared by: _______________________________________ Date: _______________ Zack Li Verified by: _______________________________________ Date: ________________ Mark Kozlowski Approved by: _______________________________________ Date: ________________ DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES This status was requested by: “third party information removed as per agreement with applicant” 2 Drug Status Report Drug: Dehydroabietylamine Drug Name Status: Dehydroabietylamine is the common name. Chemical Name: 1-Phenanthrenemethanamine, 1,2,3,4,4a,9,10,10a-octahydro- 1,4a-dimethyl-7-(1-methylethyl)-, (1R,4aS,10aR)- Other Names: leelamine; Amine D; 13-isopropylpodocarpa-8,11,13-trien-15-amine; podocarpa- 8,11,13-trien-15-amine, 13-isopropyl- Chemical structure: Molecular Formula: C20H31N CAS-RN: 1446-61-3 Pharmacological class / Application: Synthetic cannabinoid International status: US: Dehydroabietylamine is not listed specifically in the Schedules to the US Controlled Substances Act and is not mentioned anywhere on the DEA website. United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances under International Control.
    [Show full text]
  • Catalog Update01 - EU Update 31/01/2013 08:12 Page 1
    Catalog Update01 - EU_Update 31/01/2013 08:12 Page 1 Catalog update High purity biochemical tools for life scientists •Receptor agonists and antagonists •Ion channel modulators •Enzyme modulators •Signaling tools € - March 2013 Discover more at www.abcam.com/biochemicals Catalog Update01 - EU_Update 31/01/2013 08:12 Page 2 Contents Receptors & Transporters Page Receptors & Transporters (continued) Page Adenosine & Purinergics Peptide Receptors 17 P1 5 Prostanoid 18 P2 5 Serotonin Adrenoceptors 5 5-HT1 18 Cannabinoid 6 5-HT2 19 Catalytic Receptors 7 5-HT3 19 Chemokine 7 5-HT4 19 Dopamine 7 5-HT5 19 Enzyme-Linked Receptors 9 5-HT6 20 G protein-coupled estrogen 10 5-HT7 20 GABA Non-selective 20 GABAA 10 Transporters 20 GABAB 10 Sigma 20 Non-selective 10 Smoothened 20 Other 11 Sphingosine 1-Phosphate Receptors 21 Transporters 11 TGR5 21 Glutamate Toll-Like Receptors 21 AMPA & Kainate 11 Transporters 21 Broad spectrum / non-selective 11 mGlu: General 12 Ion Channels Page mGlu: Group I 12 Calcium 22 mGlu: Group I & II 12 Chloride 22 mGlu: Group II 12 Cyclic nucleotide-gated 22 mGlu: Group III 13 Ionophores, indicators & chelators 22 NMDA: AP-2 binding site 13 Other 22 NMDA: Glutamate Site 13 Potassium 22 NMDA: Glycine Site 13 Sodium 23 NMDA: Ion Channel Site 13 TRP 23 NMDA: Polyamine Site 14 Transporters 14 Enzymes Page Glycine 14 ATPase & GTPase 23 Histamine 14 Caspase 24 Imidazoline 15 Cholinesterase 24 Melatonin 15 Coenzymes 24 Muscarinic 15 Cyclase 24 Nicotinic 15 Cyclooxygenase 24 Nuclear Receptors 16 Cytochrome P450 25 Opioids 16 Deacetylase
    [Show full text]
  • PRODUCT INFORMATION Bio-Active Lipid I Screening Library (96-Well) Item No
    PRODUCT INFORMATION Bio-Active Lipid I Screening Library (96-Well) Item No. 10506 • Batch No. 0608063 Panels are routinely re-evaluated to include new catalog introductions as the research evolves. Page 1 of 35 Plate Well Contents Item Number 1 A1 Unused 1 A2 Prostaglandin A1 10010 1 A3 1-Arachidonoyl Lysophosphatidic Acid 10019 (ammonium salt) 1 A4 POV-PC 10031 1 A5 N-(α-Linolenoyl) Tyrosine 10032 1 A6 10-Nitrolinoleate 10037 1 A7 PGPC 10044 12,14 1 A8 15-deoxy-Δ -Prostaglandin A1 10065 1 A9 15-epi Prostaglandin A1 10070 1 A10 16,16-dimethyl Prostaglandin A1 10080 1 A11 N-Oleoyl Dopamine 10115 1 A12 Unused 1 B1 Unused 1 B2 Prostaglandin F2α-1-glyceryl ester 10139 1 B3 Prostaglandin E2-1-glyceryl ester 10140 1 B4 N-Arachidonoyl-3-hydroxy-γ-Aminobutyric Acid 10158 1 B5 Arachidonoyl p-Nitroaniline 10168 1 B6 1-Palmitoyl-2-hydroxy-sn-glycero-3-PC 10172 1 B7 Arachidonoyl Ethanolamide Phosphate 10180 1 B8 Prostaglandin D2 serinol amide 10192 1 B9 Prostaglandin E2 serinol amide 10193 1 B10 Prostaglandin F2α serinol amide 10194 1 B11 Prostaglandin A2 10210 1 B12 Unused 1 C1 Unused 1 C2 13,14-dihydro-15-keto Prostaglandin A2 10260 12,14 1 C3 15-deoxy-Δ -Prostaglandin A2 10265 1 C4 16,16-dimethyl Prostaglandin A2 10280 1 C5 16-phenoxy tetranor Prostaglandin A2 10285 1 C6 17-phenyl trinor Prostaglandin A2 10288 1 C7 17-phenyl trinor-13,14-dihydro Prostaglandin A2 10290 1 C8 7-hydroxycoumarinyl-γ-Linolenate 10556 1 C9 CAY10631 10562 1 C10 Heneicosapentaenoic Acid 10670 1 C11 (±)-Jasmonic Acid-Isoleucine 10740 1 C12 Unused WARNING CAYMAN CHEMICAL THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.
    [Show full text]
  • The Galway Neuroscience Centre's Christmas Research Day 2018
    The Galway Neuroscience Centre’s Christmas Research Day 2018 th (14 Dec, HBB, from 9 am) Spot prize for the best (i.e. worst!) Xmas jumper! Galway Neuroscience Centre’s Christmas Research Day Friday 14th December 2018 9:00 Arrival 9:15 Dr Dara Cannon Meeting opening Dr Kathy Ruddy, TCD A different state of mind; Regulating motor cortical excitability 9:30 NSI Early Career Researcher 2018 using TMS-based neurofeedback Dr Sarah Roche, UCC 10:00 Progesterone: A promising treatment for inherited blinding disease NSI Early Career Runner-Up 2018 10:30 Coffee & Poster Judging Prof Colm McDonald 11:00 A Clinical Overview of Psychotic Illness Discipline Enrico Bagnoli The effect of DOPAL on the bioenergetic performances of primary 11:30 CÚRAM olfactory bulb mixed cultures James Britton Developing a Bioink to 3D printing nerve guidance conduits to 11:35 CÚRAM promote nerve regeneration Silvia Cabre The potential of multi-modal collagen hydrogels for Parkinson’s 11:40 Pharmacology disease Joan Fitzgerald 11:45 Investigating the genetics of cognitive resilience in healthy ageing Biochemistry Mairead Flynn SDCCAG8 is a schizophrenia risk gene that is required for efficient 11:50 Biochemistry primary ciliogenesis Differential effects of optogenetic modulation of rat anterior Sarah Jarrin 11:55 cingulate cortical glutamatergic neurons on the affective and Pharmacology sensory components of pain Investigation of the effects of pre-operative administration of Orlaith Mannion 12:00 FAAH inhibitors in a rat model of post-operative pain following Pharmacology
    [Show full text]
  • A Brief Overview of the Antitumoral Actions of Leelamine
    biomedicines Review A Brief Overview of the Antitumoral Actions of Leelamine Myriam Merarchi 1,2 , Young Yun Jung 3, Lu Fan 2, Gautam Sethi 2,* and Kwang Seok Ahn 3,* 1 Faculty of Pharmacy, University of Paris Descartes, 75006 Paris, France 2 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore 3 College of Korean Medicine, Kyung Hee University, 24 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea * Correspondence: [email protected] (G.S.); [email protected] (K.S.A.) Received: 18 June 2019; Accepted: 15 July 2019; Published: 19 July 2019 Abstract: For the last couple of decades, natural products, either applied singly or in conjunction with other cancer therapies including chemotherapy and radiotherapy, have allowed us to combat different types of human cancers through the inhibition of their initiation and progression. The principal sources of these useful compounds are isolated from plants that were described in traditional medicines for their curative potential. Leelamine, derived from the bark of pine trees, was previously reported as having a weak agonistic effect on cannabinoid receptors and limited inhibitory effects on pyruvate dehydrogenase kinases (PDKs). It has been reported to possess a strong lysosomotropic property; this feature enables its assembly inside the acidic compartments within a cell, such as lysosomes, which may eventually hinder endocytosis. In this review, we briefly highlight the varied antineoplastic actions of leelamine that have found implications in pharmacological research, and the numerous intracellular targets affected by this agent that can effectively negate the oncogenic process. Keywords: leelamine; malignancies; molecular mechanisms, preclinical models 1.
    [Show full text]
  • Natural Phytochemicals Derived from Gymnosperms in the Prevention and Treatment of Cancers
    International Journal of Molecular Sciences Review Natural Phytochemicals Derived from Gymnosperms in the Prevention and Treatment of Cancers Tayyebeh Ghaffari 1,2 , Joo-Hyun Hong 3, Solmaz Asnaashari 4, Safar Farajnia 1, Abbas Delazar 5, Hamed Hamishehkar 1,* and Ki Hyun Kim 3,* 1 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 15731, Iran; [email protected] (T.G.); [email protected] (S.F.) 2 Student Research Committee, Tabriz University of Medical Sciences, Tabriz 15731, Iran 3 School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea; [email protected] 4 Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz 15731, Iran; [email protected] 5 Research Center for Evidence based Medicine, Tabriz University of Medical Sciences, Tabriz 15731, Iran; [email protected] * Correspondence: [email protected] (H.H.); [email protected] (K.H.K.); Tel.: +98-41-3363311 (H.H.); +82-31-290-7700 (K.H.K.) Abstract: The incidence of various types of cancer is increasing globally. To reduce the critical side effects of cancer chemotherapy, naturally derived compounds have been considered for cancer treatment. Gymnosperms are a group of plants found worldwide that have traditionally been used for therapeutic applications. Paclitaxel is a commercially available anticancer drug derived from gymnosperms. Other natural compounds with anticancer activities, such as pinostrobin and pinocembrin, are extracted from pine heartwood, and pycnogenol and enzogenol from pine bark. Citation: Ghaffari, T.; Hong, J.-H.; Gymnosperms have great potential for further study for the discovery of new anticancer compounds. Asnaashari, S.; Farajnia, S.; Delazar, This review aims to provide a rational understanding and the latest developments in potential A.; Hamishehkar, H.; Kim, K.H.
    [Show full text]
  • Cannabinoid Receptor Ligands
    Cannabinoid Receptor Ligands Roger G Pertwee School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK. Phone: + 44 (0)1224 555740, Fax: + 44 (0)1224 555844, E-mail: [email protected] Roger Pertwee is currently Professor of Neuropharmacology at the University of Aberdeen and Director of Pharmacology for GW Pharmaceuticals. His research focuses on the pharmacology of cannabis and its constituents and of cannabinoid receptors and cannabis-derived, synthetic and endogenous ligands for these receptors. The Endocannabinoid System including immune cells. CB2 receptors are located predominantly in immune cells both within and Two types of cannabinoid receptor have so far been outside the central nervous system, the functions identified.1,2 These are the CB receptor, cloned 1 of these receptors including modulation of cytokine in 1990,3 and the CB receptor, cloned in 1993,4 2 release and of immune cell migration. In the brain, both of which are members of the superfamily of CB receptors are expressed by microglia,7 by blood G-protein-coupled receptors. The cloning of these 2 vessels,7 and by some neurons.8,9 However, the role receptors prompted the development of mice from of neuronal CB2 receptors is currently unknown. which cannabinoid CB1 and/or CB2 receptors have been genetically deleted and these transgenic The central distribution pattern of CB1 receptors is animals, particularly CB1 knockout mice, are now heterogeneous and accounts for several prominent widely used to explore the physiological and pharmacological properties of CB1 receptor agonists, pathological functions of cannabinoid receptors.1,5,6 for example their ability to impair cognition and CB1 receptors are found mainly at the terminals of memory and to alter the control of motor function.
    [Show full text]
  • ICRS2014 Preliminary Programme
    TH 24 ANNUAL SYMPOSIUM OF THE INTERNATIONAL CANNABINOID RESEARCH SOCIETY BAVENO ITALY JUNE 28 - JULY 3, 2014 PRELIMINARY PROGRAMME TH 24 ANNUAL SYMPOSIUM OF THE INTERNATIONAL CANNABINOID RESEARCH SOCIETY BAVENO JUNE 28 – JULY 3, 2014 ICRS Sponsors Government Sponsors National Institute on Drug Abuse Non- Profit Organization Sponsors Kang Tsou Memorial Fund 2014 Symposium on the Cannabinoids Conference Coordinators Cecilia Hillard, Ph.D. Daniela Parolaro, Ph.D. Tiziana Rubino, Ph.D. Ethan Russo, M.D. Jason Schechter, Ph.D. Programme Committee Steve Alexander, Ph.D. Tiziana Bisogno, Ph.D. Heather B Bradshaw, Ph.D. Vincenzo Di Marzo, Ph.D. Michelle Glass, Ph.D. Matthew Hill, Ph.D Mary Lynch, Ph.D. Mauro Maccarrone, Ph.D. Sean McAllister, Ph.D. Daniela Parolaro, Ph.D. Roger G. Pertwee, M.A., D.Phil., D.Sc. Julian Romero Paredes, Ph.D. Tiziana Rubino, Ph.D. Ethan Russo, M.D. Miriam Schneider, Ph.D. Michelle Sexton, N.D. Ryan Vandrey, Ph.D. Jenny Wiley, Ph.D. Committee on Awards Steve Kinsey, Ph.D., Chair Sachin Patel, M.D., Ph.D. Student Award Committee Chair Eliot Gardner, Ph.D. Mechoulam Award Committee Francis Barth, Ph.D. Benjamin Cravatt, Ph.D. Vincenzo Di Marzo, Ph.D. Cecilia Hillard, Ph.D. Allyn Howlett, Ph.D. John Huffman, Ph.D. George Kunos, M.D., Ph.D. Gerard Le Fur, Ph.D. Aron Lichtman, Ph.D. Ken Mackie, M.D. Alex Makriyannis, Ph.D. Roger Pertwee, D.Phil, D.Sc. Raj Razdan, Ph.D. Patti Reggio, Ph.D. Murielle Rinaldi- Carmona, Ph.D. 2014 ICRS Board of Directors Executive Director Cecilia Hillard, Ph.D.
    [Show full text]